Maintaining CDK4/6 inhibition constrains drug‑resistant breast tumors by delaying cell‑cycle entry, and adding CDK2 inhibition further deepens control to guide post‑progression therapy.

The room we are in is locked. It is windowless and lit from above by a fluorescent bulb. In the hallway outside—two stories beneath the city of London—attendants in dark suits patrol silently, giving ...